Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDAP NASDAQ:HYPR NASDAQ:ICCM NASDAQ:NXL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDAPEdap Tms$1.47-2.3%$1.77$1.26▼$5.27$56.28MN/A99,024 shs68,038 shsHYPRHyperfine$0.81+0.6%$0.71$0.53▼$1.90$62.27M1.01895,275 shs98,821 shsICCMIceCure Medical$1.01-1.9%$1.02$0.48▼$1.66$60.46M0.31485,302 shs390,185 shsNXLNexalin Technology$1.02-1.0%$1.14$0.59▼$4.49$17.69M3.7568,908 shs93,567 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDAPEdap Tms-2.33%-4.17%-14.04%+12.21%-70.30%HYPRHyperfine+0.63%+3.34%+11.50%+20.40%-24.06%ICCMIceCure Medical-1.94%-12.04%+3.91%-11.40%+34.70%NXLNexalin Technology-0.97%+6.03%-11.30%-38.55%-28.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDAPEdap Tms3.0508 of 5 stars3.25.00.00.02.71.70.6HYPRHyperfine3.1484 of 5 stars3.34.00.00.02.72.50.6ICCMIceCure Medical2.317 of 5 stars3.83.00.00.02.10.00.6NXLNexalin Technology2.9879 of 5 stars3.55.00.00.02.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDAPEdap Tms 2.33Hold$8.50478.23% UpsideHYPRHyperfine 2.67Moderate Buy$1.0631.68% UpsideICCMIceCure Medical 3.50Strong Buy$2.50147.52% UpsideNXLNexalin Technology 3.00Buy$5.00390.20% UpsideCurrent Analyst Ratings BreakdownLatest NXL, HYPR, EDAP, and ICCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/29/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.505/15/2025EDAPEdap TmsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.68(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDAPEdap Tms$69.18M0.79N/AN/A$1.18 per share1.25HYPRHyperfine$12.89M4.86N/AN/A$0.67 per share1.20ICCMIceCure Medical$3.29M18.02N/AN/A$0.12 per share8.42NXLNexalin Technology$170K103.08N/AN/A$0.28 per share3.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDAPEdap Tms-$20.58M-$0.62N/AN/AN/A-34.45%-51.42%-26.43%8/27/2025 (Estimated)HYPRHyperfine-$40.72M-$0.54N/AN/AN/A-343.42%-74.19%-62.40%8/14/2025 (Estimated)ICCMIceCure Medical-$15.32M-$0.28N/AN/AN/A-467.37%-182.26%-112.65%8/19/2025 (Estimated)NXLNexalin Technology-$7.61M-$0.83N/A∞N/A-6,529.77%-277.92%-245.37%8/14/2025 (Estimated)Latest NXL, HYPR, EDAP, and ICCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2025Q1 2025ICCMIceCure Medical-$0.08-$0.06+$0.02-$0.06$0.75 million$0.73 million5/15/2025Q1 2025EDAPEdap Tms-$0.16-$0.20-$0.04-$0.20$16.56 million$16.37 million5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 million5/13/2025Q1 2025NXLNexalin Technology-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDAPEdap TmsN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDAPEdap Tms0.101.741.21HYPRHyperfineN/A6.075.48ICCMIceCure Medical0.021.891.48NXLNexalin TechnologyN/A4.564.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDAPEdap Tms62.74%HYPRHyperfine15.03%ICCMIceCure Medical0.62%NXLNexalin Technology0.65%Insider OwnershipCompanyInsider OwnershipEDAPEdap Tms0.23%HYPRHyperfine30.98%ICCMIceCure Medical2.44%NXLNexalin Technology25.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDAPEdap Tms23037.39 million37.31 millionOptionableHYPRHyperfine19077.83 million53.72 millionOptionableICCMIceCure Medical6058.70 million57.27 millionNot OptionableNXLNexalin Technology317.18 million12.84 millionNot OptionableNXL, HYPR, EDAP, and ICCM HeadlinesRecent News About These CompaniesNexalin and FatPipe Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVMay 30, 2025 | usatoday.comNexalin Technology, Inc.: Strategic Advancements and Financial Stability Justify Buy RatingMay 29, 2025 | tipranks.comJoin Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3May 28, 2025 | finance.yahoo.comNexalin Technology, Inc. to Host Investor Webinar Showcasing Innovative Neurostimulation Advances on June 3, 2025May 28, 2025 | quiverquant.comQJoin Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3May 28, 2025 | globenewswire.comNexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging DataMay 13, 2025 | finance.yahoo.comNexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging DataMay 13, 2025 | globenewswire.comNexalin Technology, Inc. Closes Public Offering of 3,850,000 Shares at $1.30 Per Share, Raising $5.0 MillionMay 6, 2025 | quiverquant.comQNexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public OfferingMay 6, 2025 | globenewswire.comNexalin Technology Announces Pricing of $5.0 Million Public Offering of Common StockMay 5, 2025 | globenewswire.comNexalin Technology, Inc. Plans Q-Submission to FDA for Gen-2 SYNC System Targeting Cognitive DisordersMay 1, 2025 | quiverquant.comQNexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA FeedbackMay 1, 2025 | globenewswire.comNexalin Technology receives IRB approval in Brazil, begins trialApril 24, 2025 | markets.businessinsider.comNexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and InsomniaApril 24, 2025 | globenewswire.comNexalin completes five phases of virtual clinic, digital research systemApril 24, 2025 | markets.businessinsider.comNexalin Technology files $50M common stock offeringApril 23, 2025 | msn.comNexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient ManagementApril 23, 2025 | globenewswire.comNexalin Technology expresses ‘strong support’ for Health Tech Investment ActApril 22, 2025 | markets.businessinsider.comNexalin Technology, Inc. Supports Health Tech Investment Act to Enhance Medicare Reimbursement for AI-Enabled Medical DevicesApril 21, 2025 | quiverquant.comQNexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled DevicesApril 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXL, HYPR, EDAP, and ICCM Company DescriptionsEdap Tms NASDAQ:EDAP$1.47 -0.04 (-2.33%) Closing price 07/15/2025 03:59 PM EasternExtended Trading$1.47 0.00 (0.00%) As of 07/15/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.Hyperfine NASDAQ:HYPR$0.80 +0.01 (+0.63%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$0.80 -0.01 (-1.24%) As of 07/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.IceCure Medical NASDAQ:ICCM$1.01 -0.02 (-1.94%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.03 +0.02 (+2.48%) As of 07:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Nexalin Technology NASDAQ:NXL$1.02 -0.01 (-0.97%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.04 +0.02 (+1.76%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
